3-hydroxy-4-(4-biphenylyl)-butyric acid | 6845-17-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-hydroxy-4-(4-biphenylyl)-butyric acid
• 英文别名: 4-(p-Biphenylyl)-3-hydroxy-buttersaeure；4-(p-Biphenylyl)-3-hydroxybuttersaeure；3-Hydroxy-4-(4-phenylphenyl)butanoic acid
• CAS: 6845-17-6
• 化学式: C₁₆H₁₆O₃
• 分子量: 256.301
• InChiKey: LJKZJVXMSWEYGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-hydroxy-4-(4-biphenylyl)-butyric acid 在 碳酸氢钠 、 三乙胺 作用下， 以 氯仿 为溶剂， 以71%的产率得到phthalidyl 3-hydroxy-4-(4-biphenylyl)butyrate
  参考文献：
  名称：

  Analgesic and anti-inflammatory arylalkanoic acid phthalidyl esters and

  摘要：

  本发明涉及具有改进的药理特性的苯基烷基酸邻苯二甲酰基酯，相对于具有镇痛和抗炎活性的相应苯基烷基酸，以及含有它们作为活性成分的药物组合物。该发明还涉及一种通过通过酯键引入邻苯二甲酰基团来改善具有镇痛和抗炎活性的苯基烷基酸的药理特性的方法。

  公开号：

  US04529737A1
• 作为产物：
  描述：

  1-([1,1'-联苯]-4-基)-3-氯丙-2-醇 在 盐酸 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成 3-hydroxy-4-(4-biphenylyl)-butyric acid
  参考文献：
  名称：

  4-（对-联苯甲酰基）-3-羟基丁酸及相关化合物的合成及抗炎活性。

  摘要：

  DOI：

  10.1021/jm00312a008

文献信息

• 5-Phenyl-Pentanoic Acid Derivatives as Matrix Metalloproteinase Inhibitors for the Treatment of Asthma and Other Diseases
  申请人：Palle Venkata P.

  公开号：US20080194565A1

  公开（公告）日：2008-08-14

  The present invention relates to C ompounds having the structure of Formula I: wherein n is an integer from 1 to 5; R 1 is optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, alkoxy, aryloxy, alkenyloxy or alkynyloxy; R 2 is alkenyl, allcynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, NR 4 R 5 , —NHC(═Y)R 4 , —NHC(═Y)NR 5 R x , —NHC(═O)OR 4 , —NHSO 2 R 4 , C(═Y)NR 4 R 5 , C(═O)OR 6 [wherein Y is oxygen or sulphur], OR 5 , —O(C═O)NR 4 R 5 , O-acyl, S(O) m R 4 , —SO 2 N(R 4 ) 2 , cyano, amidino or guanidino [wherein R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl and m is an integer 0-2; R 5 is hydrogen or R 4 ; R x is R 4 or —SO 2 N(R 4 ) 2 and R 6 is hydrogen, alkyl, cycloalkyl, aralkyl, heteroarylalkyl, heterocyclylalkyl or cycloalkylalkyl]; R 3 is hydrogen, fluorine, alkyl, cycloalkylalkyl or aralkyl; A is OH, OR 4 , —OC(═O)NR 4 R 5 , O-acyl, NH 2 , NR 4 R 5 , —NHC(═Y)R 4 , —NHC(═Y)NR 5 R x , —NHC(═O)OR 4 , —NHSO 2 R 4 , and to processes for the synthesis of the same. This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by over-expression and over-activation of an matrix metalloproteinase, using the compounds.

  本发明涉及具有以下结构的化合物：其中n是1到5之间的整数；R1是可选择地取代的烷基、烯基、炔基、环烷基、芳基、杂环烷基、杂芳基、芳基烷基、烷氧基、芳氧基、烯基氧基或炔基氧基；R2是烯基、炔基、芳基、杂环烷基、杂芳基、环烷基、NR4R5、—NHC(═Y)R4、—NHC(═Y)NR5Rx、—NHC(═O)OR4、—NHSO2R4、C(═Y)NR4R5、C(═O)OR6[其中Y是氧或硫]、OR5、—O(C═O)NR4R5、O-酰基、S(O)mR4、—SO2N(R4)2、氰基、胺基亚胺基或胍基[其中R4是烷基、烯基、炔基、环烷基、芳基、杂环烷基、杂芳基、芳基烷基、杂芳基烷基、杂环烷基烷基或环烷基烷基，m是0-2的整数；R5是氢或R4；Rx是R4或—SO2N(R4)2，R6是氢、烷基、环烷基、芳基烷基、杂芳基烷基、杂环烷基烷基或环烷基烷基]；R3是氢、氟、烷基、环烷基烷基或芳基烷基；A是OH、OR4、—OC(═O)NR4R5、O-酰基、NH2、NR4R5、—NHC(═Y)R4、—NHC(═Y)NR5Rx、—NHC(═O)OR4、—NHSO2R4等，以及其合成方法。本发明还涉及含有本发明化合物的药理学组合物，以及治疗哮喘、类风湿关节炎、慢性阻塞性肺病、鼻炎、骨关节炎、银屑病性关节炎、牛皮癣、肺纤维化、肺部炎症、急性呼吸窘迫综合征、牙周炎、多发性硬化症、牙龈炎、动脉粥样硬化、新生内膜增生导致再狭窄和缺血性心力衰竭、中风、肾脏疾病、肿瘤转移和其他炎症性疾病的方法，这些疾病特征是矩阵金属蛋白酶的过度表达和过度激活，使用这些化合物。
• MATRIX METALLOPROTEINASE INHIBITORS
  申请人：Sattigeri Viswajanani J.

  公开号：US20100081610A1

  公开（公告）日：2010-04-01

  The present invention relates to β-hydroxy and amino substituted carboxylic acids, which act as matrix metalloprotease inhibitors, particularly diastereomerically pure β-hydroxy carboxylic acids, corresponding processes for the synthesis of and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase using the compounds.

  本发明涉及β-羟基和氨基取代的羧酸，其作为基质金属蛋白酶抑制剂，尤其是对映异构体纯的β-羟基羧酸，以及合成该类化合物和含有本发明化合物的制药组合物的相关过程。本发明化合物在治疗各种炎症、自身免疫和过敏性疾病方面有用，例如治疗哮喘、类风湿性关节炎、慢性阻塞性肺疾病、鼻炎、骨关节炎、银屑病性关节炎、牛皮癣、肺纤维化、创伤愈合障碍、肺炎炎症、急性呼吸窘迫综合征、牙周炎、多发性硬化症、牙龈炎、动脉粥样硬化、新内膜增生导致再狭窄和缺血性心力衰竭、中风、肾脏疾病、肿瘤转移以及其他以基质金属蛋白酶过度表达和过度活化为特征的炎症性疾病的方法中使用该化合物。
• Matrix metalloproteinase inhibitors
  申请人：Ranbaxy Laboratories Limited

  公开号：EP2322507A1

  公开（公告）日：2011-05-18

  The present invention relates to β-hydroxy and amino substituted carboxylic acids, which act as matrix metalloprotease inhibitors, particularly diastereomerically pure β-hydroxy carboxylic acids, corresponding processes for the synthesis of and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase using the compounds.

  本发明涉及作为基质金属蛋白酶抑制剂的β-羟基和氨基取代的羧酸，特别是非对映异构纯的β-羟基羧酸，以及合成本发明化合物的相应工艺和含有本发明化合物的药物组合物。本发明的化合物可用于治疗各种炎症、自身免疫性和过敏性疾病，如治疗哮喘、类风湿性关节炎、慢性阻塞性肺病、鼻炎、骨关节炎、银屑病关节炎、牛皮癣、肺纤维化、伤口愈合障碍、肺部炎症、急性呼吸窘迫综合征、牙周炎、多发性硬化症、多发性骨髓瘤、多发性硬化症、多发性硬化症的方法、牙周炎、多发性硬化症、牙龈炎、动脉粥样硬化、导致再狭窄和缺血性心力衰竭的新内膜增生、中风、肾脏疾病、肿瘤转移，以及其他以基质金属蛋白酶过度表达和过度激活为特征的炎症性疾病。
• 5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES
  申请人：Ranbaxy Laboratories Limited

  公开号：EP1856063A1

  公开（公告）日：2007-11-21
• PROCESS FOR PREPARING MATRIX METALLOPROTEINASE INHIBITORS AND CHIRAL AUXILIARY THEREFOR
  申请人：Ranbaxy Laboratories Limited

  公开号：EP2074093B1

  公开（公告）日：2012-10-10